Kareem Saad

Dec 22, 2017

Sema4 has appointed Kareem Saad as chief strategy officer. Saad was previously chief commercial officer and executive vice president of strategy and business development for Source Medical Solutions. Before that he was a director in Dell's Healthcare and Life Sciences division. He has held a number of excutive leadership roles at midsize and early-stage biotech and healthcare IT companies, and began his career by co-founding InphoGene Bionformatics.

More Like This

May 18, 2018

William Denman

William Denman, chief medical officer and founding member of Premaitha Health, has stepped down as director and consultant to the company.

May 15, 2018

Jeffrey Bluestone, Vijay Kuchroo, Christoph Lengauer, Aviv Regev, Ramnik Xavier, Alexis Borisy, Jeff Ross, Anthony Philippakis, Maya Said, Jason Coloma, Susan O'Connor

Celsius Therapeutics has named its founders and leadership team.

The company's founders are Jeffrey Bluestone, president and CEO of the Parker Institute for Cancer Immunotherapy at the University of California, San Francisco; Vijay Kuchroo, professor of neurology at Harvard Medical School; Christoph Lengauer, venture partner at Third Rock Ventures; Aviv Regev, chair of the faculty, core member, and director of the Klarman Cell Observatory at the Broad Institute; and Ramnik Xavier, chief of gastroenterology at Massachusetts General Hospital. Lengauer is also Celsius' president.

Alexis Borisy, a partner at Third Rock Ventures, serves as executive chairman of the company's board of directors, and Lengauer is a board member. Regev is a board observer, along with Jeff Ross, cofounder of Syfr, and Anthony Philippakis, a venture partner at GV (formerly Google Ventures).

The firm's management team includes Maya Said, chief operating officer; Jason Coloma, chief business officer; and Susan O'Connor, chief people officer.

May 15, 2018

Rolland Carlson, Tanja Dowe, Katleen Verleysen

Immunexpress has appointed Rolland Carlson, Tanja Dowe, and Katleen Verleysen to its board. The company also noted that Bea Arnold has stepped down from the board after a three-year tenure.

Carlson was appointed CEO of Immunexpress last month, and previously served as president and CEO at both WaferGen Biosystems and Asuragen. Dowe currently serves as CEO of Debiopharm Innovation Fund, the strategic corporate fund of Debiopharm Group. Verleysen is CEO of CellSeeQ. Prior to that, she held various positions at Pronota, including CEO and chief operating officer.

May 15, 2018

Vasudev Rangadass

L7 Informatics (formerly Lab7 Systems) has named Vasudev Rangadass as its CEO. Rangadass joined the company from NantHealth, where he served as chief strategy officer following NantHealth's acquisition of Net.Orange, a company Rangadass founded to provide enterprise solutions to the healthcare industry. Prior to Net.Orange he was the first employee of i2 Technologies.

May 14, 2018

Greg Shaw

Angle announced today that it has appointed Greg Shaw to its scientific advisory board. Shaw is currently a consultant urological surgeon at the University College Hospital in London. He is also chief investigator for two studies at the National Institute for Health Research investigating the effects of refinements to robotic surgery and the use of drugs to prevent progression in men on active surveillance for prostate cancer. 

May 08, 2018

Stephanie Bywater

Stephanie Bywater has been appointed chief compliance officer at NeoGenomics. Her appointment became effective May 1, and she replaces Steven Jones, who will remain an executive vice president and board member at the company. Jones and NeoGenomics reached an agreement in November 2016 where he would reduce his time commitment to the firm, effective May 1 2018.

Bywater has been compliance officer at NeoGenomics since May 2017 when she joined the firm. She was previously global compliance operations and Americas compliance officer at Varian Medical Systems. Before that, she was the compliance and prvacy officer for Myriad Genetics. 

May 08, 2018

Michael Stocum

Michael Stocum has stepped down as CEO of Inivata "to pursue other interests," according to the company. Inivata said it has initiated a search for a new CEO.

May 08, 2018

Terry Pizzie

Horizon Discovery Group has appointed Terry Pizzie as CEO and board member, effective immediately. Pizzie joined Horizon in 2017 as head of commercial operations and has nearly 30 years of experience in the biotechnology tools sector. Prior to joining Horizon, Pizzie worked for Pacific Biosciences, first as a vice president in Europe, and later as head of global sales. His previous leadership roles include director of global commercial operations at Genetix prior to its acquisition by Danaher, and senior vice president of global commercial operations at Swedish biotech firm Biacore. He started his career at Applied Biosystems in 1988.

May 04, 2018

Berndt Modig

Centogene announced today that it has appointed Berndt Modig to its supervisory board. Modig currently serves as director and audit committe chair of Axovant Sciences, member of the audit committee of Affimend, and vice chairman of the supervisory board and chair of the audit committee at Kiadis Pharma. In addition, Modig is currently CEO and co-founder of Pharvaris.

Modig previously served as CFO of Prosensa Hodling from Mar. 2010 until its 2015 acquisiotn by BioMarin Pharmaceutical. Prior to Prosensa holding, Modig was CFO at Jerini AG. Modig has also held a variety of senior management positions at Surplex AG, Hayward Industrial Products, Agra Industrial, and Price Waterhouse. 

May 04, 2018

Charles Bodner

Becton Dickinson has elected Charles Bodner to the role of senior vice president of corporate finance and chief accounting officer. Effective July 1, 2018, Bodner will replace John Gallagher, who will transition to another senior role at BD. Bodner has been BD's senior vice president and CFO of the firm's medical segment since 2013, and CFO of the international business segment since 2017.

May 04, 2018

Alberto Mas, Patrick Kaltenbach, Bill Tozzi

Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.

Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Mas was head of Life Sciences for two years, and previously served as president of three of the firms other major business units. 

Kaltenbach will replace Mas effective May 29, 2018. He previously served as senior vice president of life sciences and applied markets at Agilent, a position he held since 2014.

Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

May 01, 2018

John Roberts

Cancer Genetics has appointed John Roberts as CEO and president. Roberts had been serving as interim CEO since February, in addition to serving as chief operating officer and executive VP of finance, positions he has held since July 2016. Roberts served as CFO for VirMedica from August 2015 to June 2016. Prior to VirMedica, Roberts served as chief financial and administrative officer for AdvantEdge Healthcare Solutions, CFO and treasurer for InfoLogix, and as CFO at public medical device and healthcare firms including Clarient and Daou Systems.

Apr 30, 2018

Maneesh Arora

Exact Sciences Chief Operating Officer Maneesh Arora will be leaving the company at the end of the year. During a conference call with analysts following the release of the company's first quarter earnings, Exact CEO Kevin Conroy announced that Arora "will transition to a life outside of Exact Sciences," adding that he will spend the rest of 2018 "focusing his operational and strategic rigor on the priority of advancing our pipeline plans to fuel our future success." The company does not anticipate finding a replacement COO at this time, Conroy noted.

Apr 30, 2018

Holger Reithinger

Holger Reithinger has resigned from Curetis' supervisory board effective April 30. He had been on the board since the company went public in 2015. Reithinger is a general partner at venture capital firm Forbion. Curetis' board now has six members. His replacement has not been named, and the company is "exploring options ... to further evolve" its board composition, Curetis said. 

Apr 25, 2018

Jacob Thaysen and Sam Raha

Agilent Technologies has appointed Jacob Thaysen president of the firm's life sciences and applied markets group, replacing Patrick Kaltenbach, who left the company on April 20. Thaysen currently serves as a senior vice president at the company and as president of its diagnostics and genomics group. He joined Agilent in 2012 as part of the acquisition of Dako, where he served as corporate vice president of R&D. Before that, Thaysen was founding partner and chief technology officer of Cantion, a research and defense application development company based in Denmark.

Agilent also announced that Sam Raha, who currently serves as senior vice president of the firm's strategy and corporate development group, will take over as president of the diagnostics and genomics group. Raha previously served as vice president of global marketing at Illumina, and vice president and general manager of the genomic assays business unit at Life Technologies. He also held the position of vice president and general manager of Agilent's Americas field operations for the life sciences and chemical analysis group from 2004 to 2007.

Thaysen's and Raha's appointments are effective immediately, and both will continue to report to Agilent President and CEO Mike McMullen, the firm said.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.